Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Clinical and Translational Oncology
Erschienen in: Clinical and Translational Oncology 3/2023

29.10.2022 | Research Article

miR-378a-3p promotes renal cell carcinoma proliferation, migration, and invasion by targeting TOB2

verfasst von: Nan Bao, Pengjie Zhang, Yanting Zhu, Peng Du, Gang Jin, Bing Wu, Tong Ding

Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, which has high metastasis. MicroRNAs (miRNAs) have been reported to participate in RCC progression. The present study aimed to understand the biological role and mechanism of miR-378a-3p in RCC.

Methods

RT-qPCR assay was used to assess miR-378a-3p and transducer of ERBB2 (TOB2) expression in RCC tissues and cell lines. CCK-8, clone formation, scratch, and transwell assays were carried out to evaluate cell proliferation, migration, and invasion. Furthermore, the target genes of miR-378a-3p were predicted by the online bioinformatics databases. Dual-luciferase reporter assay was used to validate the relationship between miR-378a-3p and TOB2.

Results

miR-378a-3p was highly expressed in RCC tissues and RCC cell lines. Besides, miR-378a-3p accelerated the progression of RCC by mediating cell proliferation, migration and invasion. More importantly, TOB2 was confirmed as a potential target gene of miR-378a-3p. The results of loss-of-function experiments showed that inhibition of TOB2 reversed the inhibitory roles of miR-378a-3p inhibitor on RCC progression.

Conclusions

miR-378a-3p promoted cell proliferation, migration and invasion through regulating TOB2 in RCC, which indicated a promising target for the treatment of RCC.
Literatur
1.
Mondlane ER, Abreu-Mendes P, Martins D, Cruz R, Mendes F. The role of immunotherapy in advanced renal cell carcinoma: review. Int Braz J Urol. 2021;47(6):1228–42.CrossRefPubMedPubMedCentral
2.
Gui CP, Wei JH, Chen YH, Fu LM, Tang YM, Cao JZ, et al. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma. Brief Bioinform. 2021. https://​doi.​org/​10.​1093/​bib/​bbab173.CrossRefPubMed
3.
4.
Rossi E, Bersanelli M, Gelibter AJ, Borsellino N, Caserta C, Doni L, et al. Combination therapy in renal cell carcinoma: the best choice for every patient? Curr Oncol Rep. 2021;23(12):147.CrossRefPubMedPubMedCentral
5.
6.
Cui J, Yuan Y, Shanmugam MK, Anbalagan D, Tan TZ, Sethi G, et al. MicroRNA-196a promotes renal cancer cell migration and invasion by targeting BRAM1 to regulate SMAD and MAPK signaling pathways. Int J Biol Sci. 2021;17(15):4254–70.CrossRefPubMedPubMedCentral
7.
Pan G, Liu Y, Shang L, Zhou F, Yang S. EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Commun (Lond). 2021;41(3):199–217.CrossRefPubMed
8.
Dessie EY, Tsai JJP, Chang JG, Ng KL. A novel miRNA-based classification model of risks and stages for clear cell renal cell carcinoma patients. BMC Bioinformatics. 2021;22(10):270.CrossRefPubMedPubMedCentral
9.
Qi Y, Wang L, Wang K, Peng Z, Ma Y, Zheng Z, et al. New mechanistic insights of clear cell renal cell carcinoma from integrated miRNA and mRNA expression profiling studies. Biomed Pharmacother. 2019;111:821–34.CrossRefPubMed
10.
Liu HT, Fan WX. MiRNA-1246 suppresses the proliferation and migration of renal cell carcinoma through targeting CXCR4. Eur Rev Med Pharmacol Sci. 2020;24(11):5979–87.PubMed
11.
Chen XF, Guo JF, Xu JF, Yin SH, Cao WL. MiRNA-206 inhibits proliferation of renal clear cell carcinoma by targeting ZEB2. Eur Rev Med Pharmacol Sci. 2019;23(18):7826–34.PubMed
12.
Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012;10:55.CrossRefPubMedPubMedCentral
13.
Fedorko M, Stanik M, Iliev R, Redova-Lojova M, Machackova T, Svoboda M, et al. Combination of MiR-378 and MiR-210 serum levels enables sensitive detection of renal cell carcinoma. Int J Mol Sci. 2015;16(10):23382–9.CrossRefPubMedPubMedCentral
14.
Winkler GS. The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol. 2010;222(1):66–72.CrossRefPubMed
15.
Shen H, Li W, Tian Y, Xu P, Wang H, Zhang J, et al. Upregulation of miR-362-3p modulates proliferation and anchorage-independent growth by directly targeting tob2 in hepatocellular carcinoma. J Cell Biochem. 2015;116(8):1563–73.CrossRefPubMed
16.
Yu BL, Peng XH, Zhao FP, Liu X, Lu J, Wang L, et al. MicroRNA-378 functions as an onco-miR in nasopharyngeal carcinoma by repressing TOB2 expression. Int J Oncol. 2014;44(4):1215–22.CrossRefPubMed
17.
Gray RE, Harris GT. Renal cell carcinoma: diagnosis and management. Am Fam Physician. 2019;99(3):179–84.PubMed
18.
Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507–24.CrossRefPubMed
19.
Muramatsu-Maekawa Y, Kawakami K, Fujita Y, Takai M, Kato D, Nakane K, et al. Profiling of serum extracellular vesicles reveals miRNA-4525 as a potential biomarker for advanced renal cell carcinoma. Cancer Genomics Proteomics. 2021;18(3):253–9.CrossRefPubMedPubMedCentral
20.
21.
Akbarzadeh M, Mihanfar A, Akbarzadeh S, Yousefi B, Majidinia M. Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer. Life Sci. 2021;285: 119984.CrossRefPubMed
22.
Cui Y, Xie M, Zhang Z. LINC00958 Involves in Bladder Cancer Through Sponging miR-378a-3p to Elevate IGF1R. Cancer Biother Radiopharm. 2020;35(10):776–88.PubMed
23.
Ding N, Sun X, Wang T, Huang L, Wen J, Zhou Y. miR-378a-3p exerts tumor suppressive function on the tumorigenesis of esophageal squamous cell carcinoma by targeting Rab10. Int J Mol Med. 2018;42(1):381–91.PubMedPubMedCentral
24.
Mao Y, Li W, Hua B, Gu X, Pan W, Chen Q, et al. Circular RNA_PDHX promotes the proliferation and invasion of prostate cancer by sponging MiR-378a-3p. Front Cell Develop Biol. 2020;8: 602707.CrossRef
25.
Yang Q, Zhao S, Shi Z, Cao L, Liu J, Pan T, et al. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling. J Exp Clin Cancer Res. 2021;40(1):120.CrossRefPubMedPubMedCentral
26.
Chanjiao Y, Chunyan C, Xiaoxin Q, Youjian H. MicroRNA-378a-3p contributes to ovarian cancer progression through downregulating PDIA4. Immun Inflamm Dis. 2021;9(1):108–19.CrossRefPubMed
27.
Ji KX, Cui F, Qu D, Sun RY, Sun P, Chen FY, et al. MiR-378 promotes the cell proliferation of non-small cell lung cancer by inhibiting FOXG1. Eur Rev Med Pharmacol Sci. 2018;22(4):1011–9.PubMed
28.
Soheilifar MH, Pornour M, Saidijam M, Najafi R, Azizi Jalilian F, Keshmiri Neghab H, et al. miR-1290 contributes to oncogenesis and angiogenesis via targeting of THBS1, DKK3 and SCAI. Bioimpacts. 2022;12(4):349–58.CrossRefPubMed
29.
30.
Jing L, Li S, Wang J, Zhang G. Long non-coding RNA small nucleolar RNA host gene 7 facilitates cardiac hypertrophy via stabilization of SDA1 domain containing 1 mRNA. J Cell Biochem. 2019;120(9):15089–97.CrossRefPubMed
31.
Zhang ZY, Gao XH, Ma MY, Zhao CL, Zhang YL, Guo SS. CircRNA_101237 promotes NSCLC progression via the miRNA-490-3p/MAPK1 axis. Sci Rep. 2020;10(1):9024.CrossRefPubMedPubMedCentral
32.
33.
Kim NH, Yoshimaru T, Chen YA, Matsuo T, Komatsu M, Miyoshi Y, et al. BIG3 inhibits the estrogen-dependent nuclear translocation of phb2 via multiple karyopherin-alpha proteins in breast cancer cells. PLoS ONE. 2015;10(6): e0127707.CrossRefPubMedPubMedCentral
34.
Chen Y, Wang C, Wu J, Li L. BTG/Tob family members Tob1 and Tob2 inhibit proliferation of mouse embryonic stem cells via Id3 mRNA degradation. Biochem Biophy Res Commun. 2015;462(3):208–14.CrossRef
35.
Feng M, Li Z, Aau M, Wong CH, Yang X, Yu Q. Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation. Oncogene. 2011;30(19):2242–51.CrossRefPubMed
Metadaten
Titel
miR-378a-3p promotes renal cell carcinoma proliferation, migration, and invasion by targeting TOB2
verfasst von
Nan Bao
Pengjie Zhang
Yanting Zhu
Peng Du
Gang Jin
Bing Wu
Tong Ding
Publikationsdatum
29.10.2022
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 3/2023
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-022-02984-8

Weitere Artikel der Ausgabe 3/2023

Clinical and Translational Oncology 3/2023 Zur Ausgabe

Research Article

ZEB1-activated Notch1 promotes circulating tumor cell migration and invasion in lung squamous cell carcinoma

Research Article

CD155 is a putative therapeutic target in medulloblastoma

Research Article

Methylation detection of circulating tumor cell miR-486-5p/miR-34c-5p in the progression of colorectal cancer

Research Article

Actual over 3-year survival after stereotactic body radiation therapy in patients with unresectable intrahepatic cholangiocarcinoma

Research Article

The role of p21-activated kinase 4 in the progression of oral squamous cell carcinoma by targeting PI3K–AKT signaling pathway

Review Article

MiR-29a-3p: a potential biomarker and therapeutic target in colorectal cancer

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise